Description: A third of development costs comes from clinical trials. Novartis wants to make them cheaper and faster.
Date: Jan 25, 2019
Questions for discussion:
- Summarize the approach being developed to reduce and control expenses?
- Why do you suppose it is only now being considered by these drug companies?
- Should investors consider this as a factor when choosing any particular firm?
Leave a Reply